U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Unknown
139594
Substance Class Protein
Created
by admin
on Sat Dec 16 10:16:22 GMT 2023
Edited
by admin
on Sat Dec 16 10:16:22 GMT 2023
Protein Sub Type
Sequence Type COMPLETE
Record UNII
0RFO7VC96N
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 1A1
Common Name English
UDP-GLUCURONOSYLTRANSFERASE 1A1
Common Name English
HUGT1A1
Common Name English
UDP-GLUCURONOSYLTRANSFERASE 1-1
Systematic Name English
UGT-1A1
Common Name English
HUMAN URIDINE DIPHOSPHATE GLUCURONOSYLTRANSFERASE 1A1
Systematic Name English
UGT1A1
Common Name English
Code System Code Type Description
CAS
400706-63-0
Created by admin on Sat Dec 16 10:16:26 GMT 2023 , Edited by admin on Sat Dec 16 10:16:26 GMT 2023
PRIMARY
UNIPROT
P22309
Created by admin on Sat Dec 16 10:16:26 GMT 2023 , Edited by admin on Sat Dec 16 10:16:26 GMT 2023
PRIMARY
WIKIPEDIA
UDP GLUCURONOSYLTRANSFERASE 1 FAMILY, POLYPEPTIDE A1
Created by admin on Sat Dec 16 10:16:26 GMT 2023 , Edited by admin on Sat Dec 16 10:16:26 GMT 2023
PRIMARY
FDA UNII
0RFO7VC96N
Created by admin on Sat Dec 16 10:16:26 GMT 2023 , Edited by admin on Sat Dec 16 10:16:26 GMT 2023
PRIMARY
Glycosylation Type HUMAN
Glycosylation Link Type Site
N 1_77
N 1_270
N 1_322
Related Record Type Details
Structure of GS-563117
INHIBITOR -> METABOLIC ENZYME
Structure of BELINOSTAT
SUBSTRATE -> METABOLIC ENZYME
Structure of ENASIDENIB
SUBSTRATE -> METABOLIC ENZYME
Structure of VORINOSTAT
SUBSTRATE -> METABOLIC ENZYME
Structure of EZOGABINE
SUBSTRATE -> METABOLIC ENZYME
Structure of C-1311
SUBSTRATE -> METABOLIC ENZYME
VOLRUBIGENE RALAPARVOVEC
EXPRESSED PROTEIN->VECTOR
Structure of ESAXERENONE
SUBSTRATE -> METABOLIC ENZYME
Structure of LETERMOVIR
SUBSTRATE -> TRANSPORTER
MINOR
Structure of BRANEBRUTINIB
INHIBITOR -> METABOLIC ENZYME
Structure of SELUMETINIB
SUBSTRATE -> METABOLIC ENZYME
Structure of INDACATEROL
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of DEFERASIROX
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of RALTEGRAVIR
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of MOTESANIB
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of TRIHYDROXYCHALCONE
SUBSTRATE -> METABOLIC ENZYME
Structure of VERINURAD
SUBSTRATE -> METABOLIC ENZYME
Structure of ESTRADIOL
SUBSTRATE -> METABOLIC ENZYME
Structure of LASOFOXIFENE
SUBSTRATE -> METABOLIC ENZYME
Structure of LENACAPAVIR
SUBSTRATE -> METABOLIC ENZYME
MINOR
Structure of TECOVIRIMAT
SUBSTRATE -> METABOLIC ENZYME
Structure of PONESIMOD
SUBSTRATE -> METABOLIC ENZYME
Structure of DOLUTEGRAVIR
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of 2-(3-FLUOROPHENYL)-5-HYDROXY-6-METHOXY-4(1H)-QUINOLINONE
INHIBITOR -> METABOLIC ENZYME
Structure of FEBUXOSTAT
SUBSTRATE -> METABOLIC ENZYME
Structure of CP-544439
SUBSTRATE -> METABOLIC ENZYME
Structure of LUMATEPERONE
SUBSTRATE -> METABOLIC ENZYME
Structure of SELICICLIB
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of ATAZANAVIR
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of REGORAFENIB ANHYDROUS
INHIBITOR -> METABOLIC ENZYME
SN-38 is metabolized by UGT1A1, it appears that regorafenib inhibits UGT1A1 in humans. The mean AUC of irinotecan and SN-38 increased by 28% and 44%, respectively, when irinotecan was administered five days after the last of seven daily doses of regorafenib.
Structure of VERICIGUAT
SUBSTRATE -> METABOLIC ENZYME
Structure of PASIREOTIDE
NON-SUBSTRATE -> METABOLIC ENZYME
in vitro study results indicate that pasireotide is not a substrate, inhibitor, or inducer for metabolic isozymes including UGT1A1 particularly at the proposed dosing range.
Structure of BAZEDOXIFENE
SUBSTRATE -> METABOLIC ENZYME
Structure of ENCORAFENIB
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of EDARAVONE
SUBSTRATE -> METABOLIC ENZYME
Structure of DAROLUTAMIDE
SUBSTRATE -> METABOLIC ENZYME
Structure of NINTEDANIB
SUBSTRATE -> METABOLIC ENZYME
Structure of TAMATINIB
INHIBITOR -> METABOLIC ENZYME
Structure of ALISERTIB
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of IDELALISIB
INHIBITOR -> METABOLIC ENZYME
INN VITRO
Structure of TRICLOCARBAN
SUBSTRATE -> METABOLIC ENZYME
Structure of Ezetimibe
SUBSTRATE -> METABOLIC ENZYME
Structure of RALOXIFENE
SUBSTRATE -> METABOLIC ENZYME
Structure of SCUTELLARIN
SUBSTRATE -> METABOLIC ENZYME
Structure of PANOBINOSTAT
SUBSTRATE -> METABOLIC ENZYME
IN VITRO
Structure of PITAVASTATIN
SUBSTRATE -> METABOLIC ENZYME
Structure of TAFAMIDIS
SUBSTRATE -> METABOLIC ENZYME
Structure of DELAFLOXACIN
SUBSTRATE -> METABOLIC ENZYME
Structure of BILIRUBIN
SUBSTRATE -> METABOLIC ENZYME
Structure of ORANTINIB
SUBSTRATE -> METABOLIC ENZYME
Structure of OLODATEROL
SUBSTRATE -> METABOLIC ENZYME
Structure of PEXIDARTINIB
INHIBITOR -> METABOLIC ENZYME
IC50
Structure of 2,3,7-TRICHLORODIBENZO-P-DIOXIN
SUBSTRATE -> METABOLIC ENZYME
Structure of Ertugliflozin
INHIBITOR -> METABOLIC ENZYME
Structure of Binimetinib
INHIBITOR -> METABOLIC ENZYME
MINOR
IC50
Structure of PRADIGASTAT
SUBSTRATE -> METABOLIC ENZYME
MAJOR
Structure of BICTEGRAVIR
SUBSTRATE -> METABOLIC ENZYME
Structure of Desloratadine
SUBSTRATE -> METABOLIC ENZYME
Structure of CABOTEGRAVIR
SUBSTRATE -> METABOLIC ENZYME
Structure of AXITINIB
SUBSTRATE -> METABOLIC ENZYME
Structure of ELTROMBOPAG
SUBSTRATE -> METABOLIC ENZYME
Structure of Belumosudil
INHIBITOR -> METABOLIC ENZYME
Inhibits at clinically relevant concentrations.
Name Property Type Amount Referenced Substance Defining Parameters References
MOL_WEIGHT:NUMBER AVERAGE(CALCULATED) CHEMICAL
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966